Table of Contents
- Does Magnolia Bark affect Testosterone levels?
- Does Magnolia Bark affect Estrogen levels?
- What is the dosage of Honokiol for treating Cancer?
- Is Honokiol effective for the treatment of Pancreatic Cancer?
- Is Honokiol useful for the treatment of Prostate Cancer?
- Want to know more?
- Sources
Does Magnolia Bark affect Testosterone levels?
Supplementation with magnolia bark may decrease testosterone levels. A study was conducted on female rats, in which the PCOS-induced animals were administered Magnolia Officinalis extract for 28 days. After the study researchers found that the treatment decreased symptoms of PCOS in the study subjects including a decrease in testosterone levels.
However, more studies on male models, research, and human studies are required to establish a direct link between Magnolia bark and testosterone levels.
Does Magnolia Bark affect Estrogen levels?
Magnolia bark may increase levels of estrogen when administered along with soy isoflavones. A study shows that the symptoms of menopause subsided when magnolia bark was administered by menopausal women along with other remedies. However, the study does not mention any direct link between the effect of magnolia treatment on estrogen levels, if any. An increase in estrogen levels may be responsible for a reduction in menopausal symptoms.
More studies and human trials are required to establish any relationship between magnolia bark and estrogen levels.
What is the dosage of Honokiol for treating Cancer?
The following dosage of Honokiol was found to be effective for treating cancer :
- Skin cancer: A study shows that topical application of 3 mg of Honokiol on an animal model decreased tumor size by 80%.
- Lung cancer: A study conducted on mice shows that 25 mg/kg administration of Honokiol for 12 days decreased 78% of the tumor volume.
- Breast cancer: In vitro studies show that Honokiol exhibits a dose-dependent anti-cancer activity. During an animal study, researchers found a 20 mg/kg dose of Honokiol in combination with other treatments increased the life span of animals by 8 days.
- Ovarian cancer: Studies report that Honokiol dosage in the range of 0.014-0.020 mg/ ml was effective in inhibiting the growth of ovarian cell lines.
- Prostate cancer: In a study, a dosage of 100 mg/ kg for 6 weeks was found effective for the treatment of prostate cancer in mice.
However, it should be noted that all the dosages mentioned are used during in-vitro or animal experiments. The dosage of a drug for cancer treatment depends on the stage, type of cancer, and many other factors. Also, regulatory agencies have not specified any dosage of honokiol for the treatment of cancer.
In the video below, Ann Christensen from White Rabbit Institute of Healing, explains how Magnolia bark is an important herb in Traditional Chinese Medicine (TCM) for treating stress, anxiety, and insomnia:
This is our recommended Magnolia supplement (Amazon’s Choice):
Is Honokiol effective for the treatment of Pancreatic Cancer?
Honokiol is effective for the treatment of pancreatic cancer because it inhibits cancer cell invasion and tumor growth.
A study conducted on pancreatic tumor cells shows that Honokiol treatment reduced tumor cell growth, migration, and invasion of other organs.
In another in-vitro study, researchers found that Honokiol treatment induced tumor cell death, and inhibited cell viability and aggressiveness of pancreatic cancer.
An in-vitro study on human pancreatic cells show that Honokiol arrested cell development and induced cell death. It also potentiated the effect of an anti-cancer agent known as Gemcitabine.
The studies concluded that Honokiol can be used as a potential anti-cancer agent for pancreatic cancer.
Is Honokiol useful for the treatment of Prostate Cancer?
Honokiol is useful for the treatment of prostate cancer because it induces the death of cancerous cells. It also protects prostate glands from testosterone by decreasing the androgen receptor activity.
In-vitro studies performed on prostate cancer cell lines demonstrated that treatment with Honokiol leads to the arrest of cancerous cell development; as a result of inhibiting different proteins associated with it.
Another study shows that Honokiol treatment interferes with the cell development cycle in prostate cancer.
In an animal study performed on mice, Honokiol and control were administered to the subjects induced with pancreatic cancer. The study revealed that the Honokiol treatment inhibited the growth of cancer tumors, decreased proliferation, and induced tumor cell death.
Want to know more?
Click the links below to access the individual topic pages:
Sources
This article makes use of information from the U.S. National Library of Medicine under the terms of the Creative Commons Attribution 4.0 International License.
- De Franciscis P, Grauso F, Luisi A, Schettino MT, Torella M, Colacurci N. Adding Agnus Castus and Magnolia to Soy Isoflavones Relieves Sleep Disturbances Besides Postmenopausal Vasomotor Symptoms-Long Term Safety and Effectiveness. Nutrients. 2017; 9(2):129.
- Nassar A, Khachab M, Zaatiti H, Kanaan A. Magnolia officinalis Ameliorates Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome in Rats. Jundishapur J Nat Pharm Prod. 2021;16(3):e106447.
- Shigemura K, Arbiser JL, Sun SY, Zayzafoon M, Johnstone PA, Fujisawa M, Gotoh A, Weksler B, Zhau HE, Chung LW. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer. 2007 Apr 1;109(7):1279-89. doi: 10.1002/cncr.22551. PMID: 17326044.
- Li Z, Liu Y, Zhao X, Pan X, Yin R, Huang C, Chen L, Wei Y. Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):95-102. doi: 10.1016/j.ejogrb.2008.02.023. Epub 2008 Apr 28. PMID: 18440692.
- Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh AP. Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med. 2012 Dec;12(10):1244-52. doi: 10.2174/156652412803833508. PMID: 22834827; PMCID: PMC3663139.
- Hu J, Chen LJ, Liu L, Chen X, Chen PL, Yang G, Hou WL, Tang MH, Zhang F, Wang XH, Zhao X, Wei YQ. Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity. Exp Mol Med. 2008 Dec 31;40(6):617-28. doi: 10.3858/emm.2008.40.6.617. PMID: 19116447; PMCID: PMC2679338.
- Chilampalli S, Zhang X, Fahmy H, Kaushik RS, Zeman D, Hildreth MB, Dwivedi C. Chemopreventive effects of honokiol on UVB-induced skin cancer development. Anticancer Res. 2010 Mar;30(3):777-83. PMID: 20392996.
- Hahm ER, Arlotti JA, Marynowski SW, Singh SV. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res. 2008 Feb 15;14(4):1248-57. doi: 10.1158/1078-0432.CCR-07-1926. PMID: 18281560.
- Hahm ER, Singh KB, Singh SV. c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells. Cell Cycle. 2016 Sep;15(17):2309-20. doi: 10.1080/15384101.2016.1201253. Epub 2016 Jun 24. PMID: 27341160; PMCID: PMC5004679.
- Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity
- Arora S, Bhardwaj A, Srivastava SK, Singh S, McClellan S, Wang B, Singh AP. Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS One. 2011;6(6):e21573. doi: 10.1371/journal.pone.0021573. Epub 2011 Jun 24. PMID: 21720559; PMCID: PMC3123370.
- Averett C, Bhardwaj A, Arora S, Srivastava SK, Khan MA, Ahmad A, Singh S, Carter JE, Khushman M, Singh AP. Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk. Carcinogenesis. 2016 Nov 1;37(11):1052-1061. doi: 10.1093/carcin/bgw096. PMID: 27609457; PMCID: PMC5091041.
- Wang Y, Liu Z, Liu Q, Han Y, Zang Y, Zhang H, Du X, Qin T, Wu Y. Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis. Cancer Manag Res. 2020;12:5243-5254